Skip to main content
Egyptian Liver Journal

Table 4 Recurrence-free survival (RFS) in low- and high-risk patients

From: Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model

Risk level

RFS (months)

95% CI

P value

Sig.

Survival (%) at

Median

SE

Lower

Upper

1 year

3 years

Low-risk

12

1.989

8.101

15.899

> 0.05

NS

50.0%

4.8%

High-risk

6

0.355

5.305

6.695

27.0%

0.0%

  1. RFS Recurrence-free survival, NS Nonsignificant, CI Confidence interval
Back to article page